AI model proves to be a heavyweight in tumor assessment: Mesothelioma patients and physicians benefit

Physicians and researchers at the Netherlands Cancer Institute have developed an AI model that outperforms physicians in evaluating treatment response in pleural mesothelioma.

Far more accurate than the current international standard criteria (RECIST), the model provides patients with greater certainty and tailored treatments.

It changes how physicians assess tumors and could accelerate the development of new treatments by making clinical trials more reliable and efficient. ...